Actively Recruiting

Phase 4
Age: 2Years - 17Years
All Genders
NCT06653634

Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial

Led by Oslo University Hospital · Updated on 2025-03-24

150

Participants Needed

7

Research Sites

266 weeks

Total Duration

On this page

Sponsors

O

Oslo University Hospital

Lead Sponsor

T

The Research Council of Norway

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare three different maintenance and step-down treatment strategies in children and adolescents with juvenile idiopathic arthritis in sustained remission. The main questions it aims to answer are: * Is the proportion of study participants with a disease flare different between each of the two drug withdrawal arms and the stable treatment arm during 12 months? * Does the proportion of study participants with a disease flare differ between the two drug withdrawal arms during 12 months? * How long time does it take before a disease flare occurs, and how long does it take before disease remission is reestablished for participants in the different treatment arms? Participants will be randomized to either A) continued stable treatment with methotrexate and tumor-necrosis alpha inhibitor (TNFi); B) gradual withdrawal of methotrexate while continued stable dose TNFi; or C) gradual withdrawal of TNFi. Participants will be examined every 4 month, and with extra visits if they experience increased symptoms or suspect a disease flare. If a flare occurs, the medications received at study inclusion will be restarted.

CONDITIONS

Official Title

Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is between 2 and less than 18 years old at the time of signing informed consent
  • Diagnosed with non-systemic Juvenile Idiopathic Arthritis according to ILAR classification
  • Inactive disease for at least 12 months confirmed at two consecutive visits and inactive disease by Wallace criteria at inclusion
  • No active uveitis for at least 24 months
  • Stable treatment with methotrexate and Tumor Necrosis Factor inhibitor for at least 6 months with allowed weight adjustments
  • Able to give signed informed consent and comply with study requirements
  • Male participants require no contraceptive measures
  • Female participants of childbearing potential must follow contraception guidance
Not Eligible

You will not qualify if you...

  • Having chronic widespread pain syndrome
  • Major uncontrolled comorbidities such as infectious, neurological, mental disease, malignancy, severe heart or renal failure, active stomach ulcers, or uncontrolled diabetes
  • Use of corticosteroids for JIA within 12 months before randomization
  • Currently participating in another randomized clinical trial
  • Drug or alcohol abuse affecting study adherence
  • Language barriers affecting study adherence
  • Pregnancy or breastfeeding
  • Any condition that may prevent compliance with study procedures
  • Unwillingness to use safe contraception for sexually active women of childbearing potential

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Haukeland University Hospital

Bergen, Norway, 5009

Actively Recruiting

2

Drammen Hospital

Drammen, Norway, 3004

Actively Recruiting

3

Hospital of Southern Norway Hospital Trust

Kristiansand, Norway, 4615

Actively Recruiting

4

Oslo University Hospital

Oslo, Norway, 0372

Actively Recruiting

5

Stavanger University Hospital

Stavanger, Norway, 4019

Actively Recruiting

6

University Hospital of North Norway

Tromsø, Norway, 9019

Actively Recruiting

7

St. Olavs Hospital

Trondheim, Norway, 7030

Actively Recruiting

Loading map...

Research Team

S

Siri Opsahl Hetlevik, MD PhD

CONTACT

A

Anna-Birgitte Aga, MD PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here